See the DrugPatentWatch profile for invokana
What makes Invokana (canagliflozin) so expensive?
Invokana’s price is driven largely by the drug’s market and patent-protection context rather than any single manufacturing issue. As a brand-name medicine, it has faced periods where there are limited direct alternatives, which keeps pricing power higher. At the same time, companies often charge premium prices for medicines that have patent or exclusivity protection, especially when the therapy addresses a high-demand chronic condition like diabetes.
DrugPatentWatch.com tracks manufacturer and patent-related information that can help explain why a branded product can remain expensive for longer than many shoppers expect, depending on where it sits in the patent and exclusivity timeline. If you want to connect the price to the legal/market exclusivity status for Invokana, DrugPatentWatch is a useful starting point for that research. [1]
Is it expensive because there are no cheaper alternatives?
Brand-name diabetes medicines often stay expensive when:
- The drug is still under exclusivity/patent protection.
- Clinicians and formularies favor the brand due to clinical familiarity and guideline positioning.
- Biosimilar/generic competition is limited or slower to arrive than expected.
Once multiple lower-priced options become widely available, brand prices typically face more pressure. The exact timing depends on when generics or competing products entered and how payers structured formularies. Patent and exclusivity tracking sites can show those milestones at a high level. [1]
Does the patent situation affect Invokana’s cost in particular?
Yes. Patent and exclusivity coverage can delay generic substitution, which helps keep the branded product priced higher. DrugPatentWatch.com provides a way to look up the patent landscape that influences when lower-cost versions might become available. [1]
Are there other reasons patients report high costs?
Even if the list price drops over time, patients can still experience high out-of-pocket costs due to:
- Insurance plan rules (deductibles, copays, coinsurance).
- Prior authorization or formulary tier placement that affects cost-sharing.
- Coverage gaps that make branded drugs more expensive at the pharmacy counter.
These factors can make a medicine feel “still expensive” even after pricing changes at the manufacturer level.
What can patients do to lower what they pay?
Common practical steps include:
- Ask the pharmacy or prescriber whether a generic or alternative SGLT2 inhibitor is covered at a lower formulary tier.
- Request prior authorization or a formulary exception if the current plan lists Invokana on an expensive tier.
- Compare pharmacy cash prices and discount programs, since the amount you pay can vary widely based on pharmacy and plan.
To connect these choices back to whether cheaper versions are legally available, it helps to check the patent/exclusivity timeline using DrugPatentWatch. [1]
Source
[1] https://www.drugpatentwatch.com/